Abstract
The present study examined how the multidrug resistance protein (MRP) 2, which is an ATP-dependent anionic conjugate transporter, also mediates transport of the chemotherapeutic cationic drug vinblastine (VBL). We show that ATP-dependent [3H]VBL (0.2 μM) uptake into membrane vesicles from Sf9 cells infected with a baculovirus encoding rabbit Mrp2 (Sf9-Mrp2) was similar to vesicles from mock-infected Sf9 cells (Sf9-mock) but could be stimulated by reduced glutathione (GSH) with a half-maximum stimulation of 1.9 ± 0.1 mM. At 5 mM GSH, initial ATP-dependent [3H]VBL uptake rates were saturable with an apparentKm of 1.5 ± 0.3 μM. The inhibitory effect of VBL on Mrp2-mediated ATP-dependent transport of the anionic conjugate [3H]leukotriene C4 was potentiated by increasing GSH concentrations. Membrane vesicles from Sf9-Mrp2 cells exhibited a ∼7-fold increase in initial GSH uptake rates compared with membrane vesicles from Sf9-mock cells. Uptake of [3H]GSH was osmotically sensitive, independent of ATP, and was trans-inhibited by GSH. The anionic conjugates estradiol-17β-d-glucuronide and leukotriene C4cis-inhibited [3H]GSH uptake but only in the presence of ATP. Whereas ATP-dependent [3H]VBL uptake was stimulated by GSH, VBL did not affect [3H]GSH uptake. Our results show that GSH is required for Mrp2-mediated ATP-dependent VBL transport and that Mrp2 transports GSH independent of VBL.
Footnotes
-
Send reprint requests to: Dr. F. G. M. Russel, University of Nijmegen, Department of Pharmacology and Toxicology 233, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands. E-mail:F.Russel{at}farm.kun.nl
-
J.B.K. is supported by the Netherlands Organization for Scientific Research through Grant 805-05.041.
- Abbreviations:
- MRP
- multidrug resistance protein
- LTC4
- leukotriene C4
- VBL
- vinblastine
- VCR
- vincristine
- GSH
- reduced glutathione
- E217βG
- estradiol-17β-d-glucuronide
- DNP-SG
- S-dinitrophenyl-glutathione
- EHBR
- Eisai hyperbilirubinemic rat strain
- DTT
- dithiothreitol
- MK571
- 3-([{3-(2-[7-chloro-2-quinolinyl]ethenyl)phenyl}-{(3-dimethyl-amino-3-oxopropyl)-thio}-methyl]thio)propanoic acid
- YCF1
- yeast cadmium factor-1
- Received January 20, 1999.
- Accepted May 21, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|